Celyad SA: Rises after CAR-T therapy shows promise in treating bowel cancer

Celyad Oncology SA

01/06/2020 17:20

** U.S.-listed shares of Belgium-based drug developer
 CYAD.O  jump 12% to $12.70 after co reports positive data from
an early-stage study of its investigational CAR-T therapy 
    ** The therapy, CYAD-101, showed encouraging clinical
activity with no evidence of graft-versus-host disease in
patients with relapsed metastatic colorectal cancer, a type of 
bowel cancer  urn:newsml:reuters.com:*:nBw6lTDhDa
    ** Two patients achieved a confirmed partial response and
nine patients showed zero disease progression, leading to a
disease control rate of 73%
    ** Enrollment in an expansion cohort assessing CYAD-101
following combination of chemotherapy drugs should commence in
Q4
    ** CAR-T cell therapy takes immune cells from a patient,
engineers them to recognize and attack cancer, and infuses them
back into the patient
    ** More than 54,460 shares traded, 2.5x times 25-DMA
    ** Shares have risen ~22% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))